Intrathoracic recurrence after carbon-ion radiotherapy for primary or metastatic lung tumors remains a major cause of cancer-related deaths. However, treatment options are limited. Herein, we report on the toxicity and efficacy of re-irradiation with carbon-ion radiotherapy for locoregionally recurrent, metastatic, or secondary lung tumors. Data of 95 patients with prior intrathoracic carbon-ion radiotherapy who were treated with re-irradiation with carbon-ion radiotherapy at our institution between 2006 and 2016 were retrospectively analyzed. Seventy-three patients (76.8%) had primary lung tumors and 22 patients (23.2%) had metastatic lung tumors. The median dose of initial carbon-ion radiotherapy was 52.8 Gy (relative biological effectiveness) and the median dose of re-irradiation was 66.0 Gy (relative biological effectiveness). None of the patients received concurrent chemotherapy.
chemotherapy. However, response rates are usually low and sustained control is uncommon. 5, 6 Therefore, treatment options are limited and re-irradiation with CIRT is sometimes required.
To date, several studies of definitive photon or proton beam reirradiation following radiotherapy for non-small-cell lung cancer (NSCLC) have been published. [7] [8] [9] [10] [11] [12] The authors reported that 5.0%-21.2%, 0.5%, and 3.0% of patients had experienced grade 3-4 lung toxicities, grade 5 lung toxicities, and grade 5 bleeding, respectively.
These findings suggest that the incidence of severe toxicities arising from photon or proton beam re-irradiation for lung tumors is not low. Consequently, the adaptation of photon or proton beam re-irradiation is controversial. Compared to photon beam radiotherapy, CIRT offers advantages in normal tissue sparing and target conformity. 1, 13 Therefore, re-irradiation with CIRT might reduce the incidence of severe toxicities that arise from re-irradiation for locoregionally recurrent lung tumors. However, the safety and efficacy of CIRT are not clearly understood because only one report on a relatively small number of patients has been published concerning the use of re-irradiation with CIRT for stage I lung tumors. 14 In this study, we retrospectively analyzed the clinical outcomes of patients treated with re-irradiation with CIRT for locoregionally recurrent, metastatic, or secondary lung tumors.
| MATERIALS AND METHODS

| Eligibility criteria
This study was approved by the Institutional Review Board of our institution. Research was carried out in accordance with the Helsinki Declaration. Re-irradiation was defined as treatment with overlap between the initial CIRT planning target volume (PTV) and the second CIRT PTV, and the third irradiation was defined as treatment with overlap between the first, second, and third CIRT PTVs.
We carried out a comprehensive clinical trial of re-irradiation with CIRT for locoregionally recurrent malignant tumors. This trial included a wide variety of cancers such as lung cancer, rectal cancer, prostate cancer, and pancreatic cancer. In this trial, the patients needed to fulfill common eligibility criteria (a performance status of 0-2, measurable tumors, no systemic therapy, such as chemotherapy, within 1 month of commencing re-irradiation with CIRT, and an estimated life expectancy of >6 months at the initiation of re-irradiation 
| Patients
Ninety-five patients met the inclusion criteria and were analyzed. Of these, eight patients (8.4%) received a third irradiation. Locoregionally recurrent, metastatic, and secondary lung tumors were diagnosed by biopsies and/or magnetic resonance imaging, computed tomography (CT), and PET/CT. The histology was confirmed in 29 patients (30.5%) by bronchoscopic or CT-guided biopsy before reirradiation with CIRT. "In-field" and "marginal" recurrences after initial irradiation were defined as recurrent lesions inside or outside of the initial PTV, respectively. All tumors were classified according to the UICC's TNM classification (6th edition). Peripheral tumors were defined as those that were not in close proximity to the segmental bronchus. Acute toxicity was defined as that occurring within 3 months from the commencement of re-irradiation with CIRT.
Acute and late toxicities were graded according to the NCI's Common Terminology Criteria for Adverse Events (version 4.0). 15 
| Carbon-ion radiotherapy
Patients were fixed using an individually tailored immobilization device (Moldcare; Alcare, Tokyo, Japan; Shellfitter; Kuraray, Osaka, Japan) and CT images were taken in the supine or prone position using the respiratory system.
Locoregionally recurrent, metastatic, and secondary lung tumors at re-irradiation with CIRT were contoured as the gross tumor volume (GTV) on CT images using PET/CT. The clinical target volume (CTV) was basically defined as the GTV plus a 2-5-mm margin. We modified the CTV to include solid fibrotic tissues around the GTV where possible. In cases where the CTV was close to the organs at risk, the CTV was reduced. The PTV was defined as the CTV plus a 5.0-mm safety margin to account for positioning errors.
The prescribed doses for CIRT are displayed in Tables S1-S3 . Carbon-ion beams were generated using a heavy ion medical accelerator in Chiba and were delivered using a respiratory gated irradiation system. 19 Irradiation was performed in 2-5 fields with 250 or 290 MeV carbon ions.
| Follow-up
After treatment, follow-up observations were carried out at 1, 3, 6, 9, and 12 months, and every 3 or 6 months after 12 months if serious complications had not occurred.
| Statistical analyses
Local control and overall survival (OS) were calculated using the Initial irradiation dose, Gy (RBE); median 52.8
Site of failure at re-irradiation, n (%)
In-field 70 (73.7)
Marginal zone 24 (25.3)
In-field (primary site) and out-of-field (MLN) 
| Toxicities
In total, one patient (1.0%) developed a grade 5 bronchopleural fistula, one patient (1.0%) developed grade 4 radiation pneumonitis, one patient (1.0%) developed grade 3 radiation pneumonitis, and one patient (1.0%) developed grade 3 chest pain ( Table 3 ).
The were observed between the groups (P = 1.00). The 2-year LC and OS rates of the primary lung cancers were 58.2% and 61.9%, respectively. Furthermore, the 2-year LC and OS rates of metastatic lung tumors were 38.4% and 62.7%, respectively.
| Local control and survival
| Prognostic factors
Univariate and multivariate analyses were carried out to identify potential prognostic factors for LC and OS among the different subgroups. Multivariate analysis revealed that sex (P = .008) and the interval between initial irradiation and re-irradiation (P = .048) were significant predictors of LC and that the CTV at re-irradiation (P = .001) was a significant predictor of OS (Table 4 ). In fact, the 2-year LC rates of male vs female patients with an interval between initial irradiation and re-irradiation of <24 months vs ≥24 months were 43.7% vs 71.6% and 45.9% vs 68.6%, respectively. In addition, the 2-year OS rates of patients with a CTV at re-irradiation of <80.0 mL vs ≥80.0 mL were 86.0% vs 40.0%, respectively. Radiation pneumonitis is generally considered a major risk after re-irradiation for lung cancer. 7 Regarding photon beam re-irradiation, several studies have shown, using stereotactic ablative radiotherapy, that grade 3-4 radiation pneumonitis is detected in 5.0%-19.0% of patients. [8] [9] [10] 12 McAvoy et al 21 evaluated the results of a large number of patients and reported that 99 patients with recurrent lung cancer who had previously received photon or proton beam radiotherapy were treated with proton radiotherapy or intensity-modulated radiation therapy for re-irradiation. Consequently, the incidence rate of grade ≥3 radiation pneumonitis was reported to be Although several studies of patients treated with definitive photon re-irradiation for lung tumors have been reported, using stereotactic ablative radiotherapy, the 2-year LC and OS rates have varied considerably (26.0%-92.0% and 29.0%-67.0%, respectively). 9, 12, 23 McAvoy et al 11 reported using proton beam re-irradiation, with 2-year locoregional control and OS rates of 24.0% and 33.0%, respectively. The LC rate, however, was not available. Chao et al 22 reported that the 2-year OS rate was 43.0%. In the present study, the 2-year LC and OS rates were 54.0% and 61.9%, respectively.
| DISCUSSION
These findings are largely comparable to those of photon and proton beam radiotherapy.
In the multivariate analysis, we found that an interval between initial irradiation and re-irradiation of ≥24 months was a significant predictor of LC after re-irradiation with CIRT. This might have arisen from the fact that patients with recurrent or aggressive lung tumors for a short duration were excluded from the group with an interval between initial irradiation and re-irradiation of ≥24 months.
Our study has several limitations. First, in addition to the limitations inherent in any single-center retrospective analysis, we included a wide variety of doses and tumor characteristics at initial CIRT that could have influenced the treatment outcome. Second, our results might underestimate late toxicity, as the median followup duration of all 95 patients undergoing re-irradiation was short (18 months). Finally, we could not produce composite plans for all patients treated with irradiation with CIRT and calculate the dosimetric parameters.
Our findings suggest that re-irradiation with CIRT could be a rea- with a CTV for re-irradiation of <80.0 mL. In the future, once we have expanded the adaptation for re-irradiation with CIRT and carried out studies of CIRT in patients with intrathoracic recurrence of lung cancer who previously received photon or proton radiotherapy, these findings should become significant.
In conclusion, re-irradiation with CIRT is associated with relatively low toxicity and moderate efficacy. Re-irradiation with CIRT could be an effective treatment option for patients with locoregionally recurrent, metastatic, or secondary lung tumors. However, further large-scale multicenter trials are warranted.
ACKNOWLEDG MENTS
We wish to thank the members of the NIRS Working Group for Lung Cancer. We also wish to thank Editage for English language editing.
T A B L E 4 Univariate and multivariate analyses of local control (LC) and overall survival (OS) in patients with locoregionally recurrent, metastatic, or secondary lung tumors re-irradiated with carbon-ion radiotherapy 
